title: Third-Line Treatment Options for Kidney Cancer.
authors.forename: Edwin M
authors.initials: EM
authors.lastname: Posadas
authors.forename: Suwicha
authors.initials: S
authors.lastname: Limvorasak
authors.forename: Robert A
authors.initials: RA
authors.lastname: Figlin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D057915:Drug Substitution; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018579:Patient Selection; D010641:Phenotype; D057285:Precision Medicine; D011237:Predictive Value of Tests; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor